Skip to main content
. Author manuscript; available in PMC: 2014 Jan 24.
Published in final edited form as: Mol Cell. 2012 Dec 6;49(2):283–297. doi: 10.1016/j.molcel.2012.10.028

Figure 6. BAF60c enhances chromatin modification of lipogenic genes in response to insulin.

Figure 6

(A) Nuclear extracts from HepG2 cells treated with insulin for 10 min were subjected to MNase assay using 80U/ml. qPCR using primers spanning 500 bp of the FAS promoter region. (B) MNase assay in HepG2 cells treated with insulin. Fold change over non-MNase treated cells. Means ± SEM. *p<0.05. (C) ChIP assay in HepG2 cells (left) and in mouse livers (right). (D) a; BAF60c protein levels in HepG2 cells infected with control or BAF60c adenovirus (top). Infected cells treated with insulin for 10 min for MNase assay (bottom). b; ChIP for the FAS promoter region in HepG2 cells after 10 min of insulin treatment using anti-H1, anti-p-H3-S10, anti-Ac-H3-K14, and anti-Pol II antibodies. qPCR for the FAS promoter. c; Nuclear run-on assay for FAS transcription in cells infected with BAF60c after insulin treatment. RT-qPCR for FAS run-on assay. d; RT-qPCR for lipogenic gene expression in cells overexpressing BAF60c. Means ± SEM. *p<0.05, **p<0.01. (E) a; BAF60c protein levels in shBAF60c adenovirus infected cells (top). MNase assays by qPCR (bottom). b; ChIP for FAS promoter in HepG2 cells after BAF60c knockdown. c; Run-on assay using RT-qPCR for FAS transcription. d; Lipogenic gene expression by RT-qPCR in BAF60c knockdown cells. Means ± SEM. *p<0.05, **p<0.01.